pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,614 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT810Endpoints607BioPharma Dive231onclive165BioSpace77Fierce Biotech75raps32fda press20globenewswire health
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • Male puberty is understudied — but when it starts may predict long-term health risks
    Due to a significant gender gap, far less is known about the health risks of early or late puberty onset among boys than girls.
    STAT · 1mo ago↗ source
  • What happens at a longevity festival?
    What happens at a longevity festival? On this week's STATus Report, Alex Hogan gets a dispatch from STAT's Sarah Todd.
    STAT · 1mo ago↗ source
  • Opinion: Grail’s multi-cancer early detection trial was negative. But as an oncologist, I see more to this story
    An oncologist shares three lessons from the world’s first randomized trial on a multi-cancer early detection.
    STAT · 1mo ago↗ source
← prev
page 34 of 65
next →
20
fda recalls20
fda medwatch16
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • Opinion: Lawmakers promised cancer patients would be protected from Medicaid cuts. Now CMS says otherwise
    “One of the cancer community’s worst fears is coming to pass,” writes Gwen Nichols of Blood Cancer United.
    STAT · 1mo ago↗ source
  • STAT+: After hospitals, patients get a turn to bring AI into the doctor’s office
    Ambient scribes were the first large-scale application of AI in health care. Now developers are pitching them as diligent note-takers for patients.
    STAT · 1mo ago↗ source
  • ADC biotech Ona Therapeutics secures $86.6M in Series B raise
    Barcelona-based Ona Therapeutics has raised $86.6 million in a Series B round to advance two ADC candidates into the clinic. CEO Valerie Vanhooren told Endpoints News in an interview that the cash…
    Endpoints · 1mo ago↗ source
  • STAT+: Trump administration to strip job protections of top NIH officials, grants staff
    Among the affected positions, which the White House estimates to be 8,000, are high-level officials who oversee research grants from the NIH.
    STAT · 1mo ago↗ source
  • Alnylam to pay $30M upfront to AI startup Inceptive in RNA R&D deal
    Alnylam Pharmaceuticals announced its first discovery-focused AI deal Wednesday, tapping a Silicon Valley biotech startup to see if AI can boost its R&D efforts. Alnylam and Inceptive signed a coll…
    Endpoints · 1mo ago↗ source
  • STAT+: Alnylam to partner with Inceptive Nucleics for AI foundation models for RNAi therapeutics
    Alnylam announced a three-year deal with Inceptive, worth up to $2 billion, with $30 million up front in cash and equity in the startup.
    STAT · 1mo ago↗ source
  • STAT+: HaloMD faces lawsuit alleging No Surprises Act middleman used ‘sham letter,’ misleading data
    Highmark Health is the fourth insurer to sue HaloMD, seeking to overturn arbitration wins.
    STAT · 1mo ago↗ source
  • Bristol Myers turns focus to AI costs after broad rollout to workers
    PALO ALTO, CA — After giving artificial intelligence tools to thousands of employees, Bristol Myers Squibb is now working to get a handle on the costs of the technology and where it’s actually crea…
    Endpoints · 1mo ago↗ source
  • Axsome pushes back generic entry for narcolepsy drug until 2040
    Axsome Therapeutics has successfully delayed generic competition for its narcolepsy drug Sunosi until 2040. The company announced on Wednesday that it has reached a settlement with the last applica…
    Endpoints · 1mo ago↗ source
  • FDA guides pharma on explaining unapproved drugs to payors
    Biopharma companies preparing to launch the next practice-changing blockbusters want payors to know what's coming before they ultimately land an FDA approval. The trick is to do that without stretc…
    Endpoints · 1mo ago↗ source
  • What it will take for more employer GLP-1 coverage
    Last week, Eli Lilly proclaimed that its weight loss shot and pill are now “covered for millions of Americans,” now that all three major pharmacy benefit managers have put the ...
    Endpoints · 1mo ago↗ source
  • Regeneron doubles down on CytomX after other pharmas walked away
    After losing a couple of pharma alliances in recent quarters, CytomX Therapeutics is getting a major lift from a key collaborator. Regeneron is doubling down on its partnership with the Bay Area bi…
    Endpoints · 1mo ago↗ source
  • Mineralys makes money moves before looming hypertension approval
    Mineralys Therapeutics first drew attention in 2021 with a bold bet on a new type of hypertension drug called lorundrostat. It came with a tiny $1 million upfront fee to the medicine's originator,…
    Endpoints · 1mo ago↗ source
  • STAT+: What the pope’s encyclical on AI means for Catholic hospitals, and all of health care
    In this edition of STAT's AI Prognosis: Brittany Trang analyzes the pope's encyclical on artificial intelligence for takeaways relevant for health care.
    STAT · 1mo ago↗ source
  • STAT+: Legend Biotech emerged as a rare market winner
    New guidance for gene therapy developers, Lilly's deal for kidney drugs, and more biotech news from The Readout
    STAT · 1mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about GLP-1 drugs and knees, FDA cell and gene therapy guidance, and more
    Taking weight loss drugs for at least three years could prevent thousands of knee replacements a year, a new study found
    STAT · 1mo ago↗ source
  • Is the military fueling eating disorders?
    A brief hantavirus update, some good news about death, and more health news from Morning Rounds
    STAT · 1mo ago↗ source
  • Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases
    Last month, Ascidian Therapeutics presented the first data suggesting a new way to fix broken genes may be safe in people. Now Eli Lilly has struck a deal with the startup. Ascidian’s ...
    Endpoints · 1mo ago↗ source
  • Top ultra-processed food researchers call for sweeping policy change: ‘The system is rigged’
    A survey finds that ultra-processed foods are a cross-partisan concern. And yet policy has been slow to follow.
    STAT · 1mo ago↗ source
  • Opinion: The medical-billing AI arms race between providers and insurance
    “The financial side effects of care have become clinical ones,” writes Darshak Sanghavi.
    STAT · 1mo ago↗ source
  • Opinion: The Amish way of health care
    “Public health is going to have to talk about the Amish more and more”: Listen to STAT’s "First Opinion Podcast" on the Amish and health care.
    STAT · 1mo ago↗ source
  • Opinion: How the military may be fueling eating disorders in men
    “Much of the rhetoric, imagery, and policy messaging from the Trump administration centers on extreme masculine ideals,” First Opinion author writes.
    STAT · 1mo ago↗ source